These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18704417)

  • 1. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.
    Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K
    Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
    Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
    Clin Cancer Res; 2009 Feb; 15(3):1059-63. PubMed ID: 19188180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
    Forrest DL; Trainor S; Brinkman RR; Barnett MJ; Hogge DE; Nevill TJ; Shepherd JD; Nantel SH; Toze CL; Sutherland HJ; Song KW; Lavoie JC; Power MM; Abou-Mourad Y; Smith CA
    Leuk Res; 2009 Feb; 33(2):271-5. PubMed ID: 18762338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
    Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
    Mauro MJ; Druker BJ; Maziarz RT
    Leuk Res; 2004 May; 28 Suppl 1():S71-3. PubMed ID: 15036945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
    Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
    J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
    White DL; Dang P; Engler J; Frede A; Zrim S; Osborn M; Saunders VA; Manley PW; Hughes TP
    J Clin Oncol; 2010 Jun; 28(16):2761-7. PubMed ID: 20421539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
    Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
    Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
    Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
    J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase.
    Palandri F; Iacobucci I; Quarantelli F; Castagnetti F; Cilloni D; Baccarani M;
    Haematologica; 2007 Nov; 92(11):1579-80. PubMed ID: 18024412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.